Myriad Genetics Stock
Myriad Genetics Stock
A loss of -1.300% shows a downward development for Myriad Genetics.
We see a rather positive sentiment for Myriad Genetics with 8 Buy predictions and 1 Sell predictions.
With a target price of 8 € there is a hugely positive potential of 75.44% for Myriad Genetics compared to the current price of 4.56 €.
So far the community has only identified positive things for Myriad Genetics stock. The most positive votes were given for criterium "EBIT growth".
Pros and Cons of Myriad Genetics in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Myriad Genetics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Myriad Genetics | -1.300% | -4.938% | -11.154% | -62.131% | -12.830% | -75.399% | -80.702% |
| Healthequity Inc. | 0.000% | 0.000% | -7.792% | -33.019% | -8.974% | 32.710% | 5.185% |
| Bruker Corp. | -2.970% | -8.979% | -9.644% | -33.821% | -9.046% | - | - |
| Omnicell Inc. | -0.970% | -5.213% | 5.263% | -7.407% | 3.093% | -26.606% | -64.602% |
Comments
Myriad Genetics (NASDAQ:MYGN) had its price target lowered by analysts at Piper Sandler from $9.00 to $8.50. They now have an "overweight" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from $12.50 to $9.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $14.00 to $8.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat